Announcements Trials
Browse Landscape

Phase

Phase 1 35Phase 2 12Phase 1/2 5Phase 4 3Phase 3 3Phase NA 1Phase 2/3 1

Status

Withdrawn 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2NETWORK 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 163Thoracic 132Genitourinary 77Gastrointestinal 41Head & Neck 39Gynecologic 13Sarcoma 4Tumor-Agnostic 3Other solid neoplasm 1CNS 1

Conditions

Neoplasm Metastasis 2Carcinoma, Squamous Cell 1Carcinoma 1Adenocarcinoma 1

Interventions

Carboplatin 8Paclitaxel 7Fluorouracil 7Cisplatin 7atezolizumab 5Trastuzumab 5Pemetrexed 5Oxaliplatin 5Leucovorin 5Bevacizumab 5pembrolizumab 4Gemcitabine 4Capecitabine 4Albumin-Bound Paclitaxel 4Surveys and Questionnaires 3Observation 3Leuprolide 3Irinotecan 3Glutamine 3Drug Therapy 3Docetaxel 3Dexamethasone 3130-nm albumin-bound paclitaxel 3trifluridine tipiracil drug combination 2regorafenib 2osimertinib 2enzalutamide 2Surgical Procedures, Operative 2Standard of Care 2Sorafenib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Docetaxel × Tumor-Agnostic × Clear all
NCT04879368 2025-07-17

INTEGRATEIIb

Australasian Gastro-Intestinal Trials Group

Phase 3 Active not recruiting
450 enrolled
Tumor-Agnostic

Adenocarcinoma, Carcinoma, Neoplasm Metastasis

NCT03811418 2019-11-26

ATTILA

iOMEDICO AG

Phase 3 Withdrawn
Tumor-Agnostic

Neoplasm Metastasis

NCT00539630 2007-10-04

TAX + Cisplatin + 5 F/U vs Cisplatin + 5 F/U in SCCHN

Sanofi

Phase 3 Completed
86 enrolled
Tumor-Agnostic

Carcinoma, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡